Euclidean Technologies Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-1,277
Closed -$235K 106
2021
Q2
$235K Buy
+1,277
New +$219K 0.19% 66

Other funds holding ALXN

Euclidean Technologies Management's ALXN Position: Q3 2021 in Review

Euclidean Technologies Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,277 shares — an estimated $235K sold.

Euclidean Technologies Management first reported a position in ALXN in Q2 2021 and held it in 1 quarter. The position peaked at $235K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Euclidean Technologies Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Euclidean Technologies Management sold 1,277 Alexion Pharmaceuticals shares in Q3 2021, an estimated $235K.
  • Euclidean Technologies Management first reported a position in Alexion Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Euclidean Technologies Management's Alexion Pharmaceuticals position peaked at $235K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Euclidean Technologies Management's 13F filing for Q3 2021, filed 2 Nov 2021.